menu
    • menu
    [{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Zina Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Resveratrol","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Jupiter Neurosciences \/ Zina Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Zina Biopharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Jupiter Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Resveratrol","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Catalent Pharma Solutions \/ Jupiter Neurosciences","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Jupiter Neurosciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Resveratrol

    Menu

    Resveratrol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Catalent Pharma Solutions

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Catalent Pharma Solutions

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Jupiter Neurosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Jupiter, Catalent Sign JOTROL Manufacturing Deal for Parkinson’s Phase 2a

                            Details : Under the agreement, Catalent Pharma will be responsible for the production of Jotrol (resveratrol) softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease.

                            Product Name : Jotrol

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 03, 2025

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Jupiter Neurosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Zina Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Jupiter, Zina Bio Partner for Phase 2a Parkinson's Trial Advancement

                            Details : The partnership aims to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease evaluating JOTROL, Jupiter’s patented resveratrol-based therapeutic platform.

                            Product Name : Jotrol

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 30, 2025

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Zina Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Dominari Securities

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

                            Details : The Company intends to use the proceeds to fund the Phase 2 trial of its product candidate Jotrol, an enhanced orally administered resveratrol formulation, in patients with Parkinson’s Disease

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 04, 2024

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Dominari Securities

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Dominari Securities

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Jupiter Neurosciences Prices $11M IPO, Lists on Nasdaq

                            Details : The Company intends to use the proceeds to fund the Phase 2 trial of its product candidate Jotrol, an enhanced orally administered resveratrol formulation, in patients with Parkinson’s Disease

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 02, 2024

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Dominari Securities

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Neurosciences

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Spartan Capital Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Neuro-inflammation Biotech Jupiter Neurosciences Revises Terms Ahead Of $15 million IPO

                            Details : Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.

                            Product Name : Jotrol

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 02, 2022

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Spartan Capital Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jupiter Orphan Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Orphan Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation

                            Details : The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.

                            Product Name : Jotrol

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 01, 2020

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jupiter Orphan Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Jupiter Orphan Therapeutics

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL™ to Phase I Clinical Trial for Alzheimer's

                            Details : The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.

                            Product Name : Jotrol

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Resveratrol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth